公开(公告)号：US20110230361A1

公开(公告)日：2011-09-22

申请号：US13129122

申请日：2009-11-13

申请人： Carlos Moreno ,  Adeboye Osunkoya ,  Wei Zhou ,  Brian Leyland-Jones ,  Qi Long ,  Brent A Johnson

发明人： Carlos Moreno ,  Adeboye Osunkoya ,  Wei Zhou ,  Brian Leyland-Jones ,  Qi Long ,  Brent A Johnson

IPC分类号： C40B30/00 ,  C12Q1/68 ,  C40B40/06

CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/16 ,  C12Q2600/178 ,  G16B25/00 ,  G16B40/00

摘要： Described herein are methods for predicting the recurrence, progression, and metastatic potential of a prostate cancer in a subject. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of FOXO1A, SOX9, CLNS1A, PTGDS, XPO1, LETMD1, RAD23B, ABCC3, APC, CHES1, EDNRA, FRZB, HSPG2, and TMPRSS2_ETV1 FUSION. The method can further comprise detecting in a sample from a subject one or more biomarkers selected from the group consisting of miR-103, miR-339, miR-183, miR-182, miR-136, and miR-221. An increase or decrease in one or more biomarkers as compared to a standard indicates a recurrent, progressive, or metastatic prostate cancer.

摘要翻译： 本文描述了用于预测受试者中前列腺癌的复发，进展和转移潜能的方法。 例如，该方法包括在受试者的一个样品中检测一种或多种选自FOXO1A，SOX9，CLNS1A，PTGDS，XPO1，LETMD1，RAD23B，ABCC3，APC，CHES1，EDNRA，FRZB，HSPG2和 TMPRSS2_ETV1 FUSION。 该方法还可以包括在受试者的样品中检测一种或多种选自miR-103，miR-339，miR-183，miR-182，miR-136和miR-221的生物标志物。 与标准物相比，一种或多种生物标志物的增加或减少表示复发，进行性或转移性前列腺癌。